SCHEMBL16437438

SCHEMBL16437438

CCc1c(C)cnn1CC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.52
▸ CTNNB1 P35222 2/20 0.48
▸ WNT3A P56704 2/20 0.48
▸ MAPT P10636 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PDE4D Q08499 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ TSHR P16473 2/20 0.45
▸ HSD11B1 P28845 2/20 0.44
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CBX7 O95931 1/20 0.43
▸ CDYL2 Q8N8U2 1/20 0.43
▸ CDYL Q9Y232 1/20 0.43
▸ CDY1; CDY1B Q9Y6F8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16437443 0.87 PDE4B (0.48) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16426583 0.83 PDE4B (0.50) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16437441 0.79 PDE4D (0.55) PDE4BCTNNB1WNT3AMAPTPDE4D
SCHEMBL16437437 0.78 PDE4B (0.51) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16426964 0.77 PDE4B (0.48) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16427211 0.77 PDE4D (0.50) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16437442 0.77 PDE4B (0.53) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL28058790 0.75 PDE4B (0.48) PDE4BCTNNB1WNT3AMAPTMEN1
SCHEMBL16427380 0.74 PDE4D (0.52) PDE4BCTNNB1WNT3AMAPTKMT2A
SCHEMBL16427745 0.74 PDE4B (0.50) PDE4BCTNNB1WNT3AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 — — US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN PDE4B 1658/4885CTNNB1 3106/4885WNT3A 3064/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN PDE4B 1728/4885CTNNB1 3052/4885WNT3A 3022/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN PDE4B 1728/4885CTNNB1 3052/4885WNT3A 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback